Anavar

Oxandrolone / var · Anabolic-androgenic steroid (oral)

Research reference only. Pepdex does not sell, supply or track this compound, and nothing here is guidance to use it — this page exists so the evidence and the risks are visible.

What it is

The most-used oral steroid in the recreational world — mild reputation, strength and hardness with little water, popular in cutting runs and among women on a reputation for lower virilisation risk — though no reliable comparative ranking across steroids actually establishes that, and the label documents potentially irreversible virilisation.

How it works

Oxandrolone is a 17-alpha-alkylated DHT derivative: the 17-alpha alkylation is what gives it oral activity and also what drives its hepatic risk. It belongs to the hepatotoxic 17-alpha-alkylated subgroup of oral anabolic steroids — a subgroup, not every orally active androgen. It does not aromatise, so there is no estrogen pathway, and its androgen-receptor binding is modest, which is the pharmacological basis of its "mild" reputation. That reputation is the problem: whatever it means, it does not extend to lipids or to suppression, and almost every misunderstanding of this drug comes from assuming it does.

What human evidence shows

One of the few AAS with real modern trial history (burn recovery, HIV wasting) — it preserves and adds lean mass. The "mild" label refers to androgenic side effects, not to safety: it is a 17-alpha-alkylated oral, which is exactly the liver-loading class.

The studies, one by one

This is, unexpectedly, one of the best-studied anabolic steroids in humans — because it had real clinical indications and real trials rather than a purely non-medical history.
Severe-burn medicine is the deepest literature: the main 235-person acute-burn trial reported lean-mass retention and shorter normalised acute hospital stay — wound healing was not a primary outcome, and the long-term paediatric follow-ups did not establish a general stay benefit. FDA's 2023 withdrawal was not a toxicity-versus-efficacy tradeoff on the burn data: it concluded there was NO substantial evidence of effectiveness for the drug's actual approved indications, and that the overall benefit-risk was unfavourable, citing peliosis hepatis, sometimes-fatal liver tumours and cholestatic hepatitis.
It carried FDA indications for weight regain after significant loss, and was studied in HIV wasting, alcoholic hepatitis, Turner syndrome and Duchenne muscular dystrophy — a genuinely broad clinical record.
The burn literature also produced the clearest lipid warning: HDL suppression was marked and consistent, in supervised patients, at therapeutic exposures.
What does not exist is a trial of physique use in healthy adults. Graded honestly: lean-mass effects in catabolic disease are MODERATE, the burn length-of-stay finding is LIMITED, and healthy physique or cutting benefit is NONE SHOWN — burn and wasting patients do not establish what happens in a healthy body, in either direction.

Half-life and how long it lasts

An oral with a short half-life — roughly nine to ten hours, far shorter than injectable esters — so blood levels rise and fall within a day rather than persisting for weeks. That short window is why people wrongly assume its effects on lipids and the hormonal axis are equally short-lived; suppression and HDL depression build over the course of use and do not clear on the same schedule as the drug. Detection in anti-doping testing outlasts the pharmacological effect substantially.

Risks

Lipids get wrecked fast — HDL suppression from orals is among the worst per-milligram. Hepatic strain (17aa), full HPTA suppression like every AAS, hair loss in the predisposed, and for women virilization that is dose- and duration-dependent and partly irreversible. Unregulated products can be mislabelled or contaminated, and composition cannot be verified from the label.

Who should never touch it

Class-level severe outcomes reported with anabolic steroids, which no compound here is exempt from: cardiac arrest, heart attack, thickened heart muscle, heart failure and stroke; serious liver injury; and mania, paranoia, psychosis, hostility, aggression, dependence and depression on withdrawal.
Pregnancy and breastfeeding: androgens can cause fetal harm including virilisation of a female fetus. Avoid in both.
Anyone with existing liver disease or an unexplained enzyme elevation — the FDA specifically cited peliosis hepatis and hepatic tumours when withdrawing approval.
Anyone with an already poor lipid profile, familial hyperlipidaemia, or cardiovascular disease.
Anyone taking warfarin or another anticoagulant without a prescriber managing the interaction.
Women who are pregnant, could become pregnant, or are unwilling to accept a non-zero risk of permanent voice change.
Anyone hoping to preserve fertility in the near term.

Interactions worth knowing

Anticoagulants — oxandrolone has one of the better-documented warfarin interactions in this class, capable of substantially increasing anticoagulant effect. This is a genuine clinical interaction, not a theoretical one.
Concurrent hepatotoxic exposures can increase risk; no safe combination has been established.
Diabetes medication — glucose control can shift.
Alcohol and other hepatically-cleared drugs add to the same load the alkylation already imposes.

Stacking interactions

Documented interactions with other things people research. A compound not listed here does not mean the combination is safe — only that no specific interaction is on file.

CautionWinstrol